Based on the provided content, here's the breakdown of CVE-2015-3459:

**Root Cause of Vulnerability:**

*   **Improper Authorization:** The Hospira LifeCare PCA Infusion System's communication module, by default, grants unauthenticated users root privileges on Port 23/TELNET.

**Weaknesses/Vulnerabilities Present:**

*   **Improper Authorization (CWE-285):** Unauthenticated users can gain root access to the device.
*   The device exposes several ports including Port 23/TELNET, Port 80/HTTP, Port 443/HTTPS, and Port 5000/UPNP

**Impact of Exploitation:**

*   An attacker can issue commands to modify the configuration of the pump, including drug libraries and software updates.
*   While the pump configuration can be modified, it is not possible to remotely operate the pump. A clinician is still required to be present at the pump to manually initiate the dosage.

**Attack Vectors:**

*   **Remote Exploitation:** The vulnerabilities can be exploited remotely due to the open ports.
*   **Network Access:** An attacker needs network access to the device.

**Required Attacker Capabilities/Position:**

*   **Low Skill:** Exploitation of the improper authorization vulnerability requires low skill.
*   **Network Access:** The attacker needs to be able to reach the device on the network.

**Additional Details:**
*   The advisory also mentions a second vulnerability, CVE-2014-5406, related to "Insufficient Verification of Data Authenticity", which allows an attacker to remotely push unauthorized modifications.
*   Hospira has released a new version (7.0) that closes ports 20/FTP and 23/TELNET by default to mitigate the risk, however the release date is pending FDA approval.
*   The CVSS v2 base score for CVE-2015-3459 is 10.0 with a vector string of (AV:N/AC:L/Au:N/C:C/I:C/A:C) indicating a high severity vulnerability.